Petrov Institute: working together to lead personalised cancer research in Russia

AstraZeneca and the N.N. Petrov Institute of Oncology, one of Russia’s leading cancer research institutions, established a ground-breaking collaboration in 2013 – the first of its kind between a global pharmaceutical company and a Russian research centre.

The aim is to assess various genes and other biomarkers within the Russian population by exploring potentially drug-sensitising gene mutations in a number of tumour types.

 

 

Related articles